Is GSK closing down?
GlaxoSmithKline plans to shut down antibiotics production in the U.K. after wrapping up a $500 million product sale to Novartis’ Sandoz. Ulverston will shut down completely, but Barnard Castle will continue manufacturing other GSK prodcuts.
What happened to GSK?
The culmination of the Consumer Healthcare string of deals will result in GSK splitting into two separate companies, via a demerger and subsequent listing of the joint venture. This will create two publicly traded companies, one focusing on pharmaceuticals and research & development, the other on consumer healthcare.
Is GSK going to split?
GSK is to split itself in two by demerging its consumer products division. A demerger can create value for shareholders (the 1+1 = 3 part) but GSK is asking investors to trust that this plays out while also having to accept a much lower dividend (the ‘-½’ part).
What is the future of GSK?
New GSK will prioritise R&D and commercial investment in Vaccines and Specialty Medicines, which are expected to grow to around three-quarters of company sales by 2026. As part of its 2021-26 outlook, Vaccines is expected to grow sales at a high single-digit % CAGR and Specialty Medicines at a double-digit % CAGR.
Are Pfizer and GSK together?
In December 2018, Pfizer and GlaxoSmithKline joined together to create a global healthcare company by combining the consumer healthcare business of each company. The combined global sales of the two consumer businesses are $12.7 billion.
What happens to shares when GSK splits?
Under GSK’s plan, shareholders will receive stock in the new consumer health group amounting to at least 80% of the 68% stake that GSK currently owns in it. Pfizer owns the remaining 32%. New GSK would sell the remaining 20% stake “in a timely manner,” the group has said.
How is recombinant vaccine made?
A recombinant vaccine is a vaccine produced through recombinant DNA technology. This involves inserting the DNA encoding an antigen (such as a bacterial surface protein) that stimulates an immune response into bacterial or mammalian cells, expressing the antigen in these cells and then purifying it from them.
What’s new in GSK’s Annual Report 2015?
B GSK Annual Report 2015 Strategic report Governance & remuneration Financial statements Investor information “ In 2015, we made substantial progress to accelerate new product sales growth, integrate new businesses in Vaccines and Consumer Healthcare and restructure our global Pharmaceuticals business.
What does GSK do?
GSK is a science-led global healthcare company that aims to deliver growth and improving returns to shareholders through the development of innovative pharmaceutical, vaccine and consumer healthcare products. Pharmaceuticals £14.2bn 2015 turnover Leadership in key therapeutic areas including Respiratory and HIV
What went wrong with GSK’s immuno-oncology drug?
The immuno-oncology drug, which fuses a TGF-β trap with an anti-PD-L1 molecule, failed a trial comparing it to Merck & Co.’s blockbuster PD-1 inhibitor Keytruda in non-small cell lung cancer (NSCLC). An independent monitoring committee told GSK the trial is unlikely to meet its primary endpoint, prompting GSK and Merck KGaA to call a halt.
Will GSK cut its dividend by 35% in 2022?
Credit Suisse downgraded its rating of GSK to “underperform,” noting that the company is facing so many challenges it may need to cut its 2022 dividend by more than 35%. “With multiple near-term and strategic challenges we see limited upside,” Credit Suisse said.